Hillstar aspires to build a portfolio of programs against autoimmune diseases with unmet or underserved medical needs.
Location: United States, Massachusetts, Boston
Employees: 1-10
Total raised: $67M
Investors 2
| Date | Name | Website |
| 10.03.2026 | Droia Onco... | droiaventu... |
| - | Life Arc V... | lifearcven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.04.2025 | Series A | $67M | - |
Mentions in press and media 4
| Date | Title | Description |
| 01.04.2025 | Hillstar Bio Secures $67 Million to Revolutionize Autoimmune Disease Treatment | In the world of biotechnology, where innovation is the lifeblood, Hillstar Bio has emerged as a beacon of hope. The Boston-based company recently secured $67 million in Series A funding, a significant leap towards transforming the treatment... |
| 01.04.2025 | Hillstar Bio: $67 Million (Series A) Raised For Developing Precision Immunotherapies To Transform Autoimmune Treatment | Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, announced the closing of a $67 million Series A funding round. This funding was led by a syndicate o... |
| 25.03.2025 | Hillstar Bio Raises $67M in Series A Financing | Hillstar Bio, a Boston, MA-based biotechnology company focused on developing immunology therapies for autoimmune diseases, raised $67M in Series A funding. Backers included Droia Ventures, Frazier Life Sciences, Novo Holdings A/S, LifeArc V... |
| - | Hillstar Bio | “Hillstar Bio |” |